Information Provided By:
Fly News Breaks for February 25, 2020
Feb 25, 2020 | 08:41 EDT
As previously reported, Evercore ISI analyst Joshua Schimmer upgraded Regeneron (REGN) to Outperform from In Line with a price target of $500, up from $400, given his view that the "stumble" for competitor Novartis' (NVS) Beovu "looks real." Yesterday it was reported that an elevated rate of vasculitis was seen in patients treated with Beovu compared to Regeneron's Eylea. The Fly notes that Jefferies analyst Biren Amin also upgraded Regeneron to Buy from Hold following the news for Novartis' competing drug.
News For REGN;SNY From the Last 2 Days
Aug 13, 2020 | 10:00 EDT
President Donald Trump tweeted: "Drug companies, which are being forced by me to substantially reduce Drug Prices, are taking $millions in ads saying I want to increase Medicare Primiums. Wrong, just the opposite! These ads show DRUG PRICES ARE GOING DOWN, and they are not happy! False advertising!" Large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link
Aug 13, 2020 | 09:26 EDT
Virtual Meeting to be held on August 14 hosted by Oppenheimer.
Aug 12, 2020 | 11:45 EDT
Large Cap & Biopharma Analysts Chen & Kim, along with Dr. Arnold Lentnek, Medical Director at Infectious Disease Medical Practice of NY, debate which company will have the best-in-class next-generation pneumococcal conjugate vaccines franchise on an Analyst/Industry conference call to be held on August 19 at 1 pm.